SACRAMENTO, Calif., Aug. 18, 2015 /PRNewswire/ -- Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer Dr. Chris Yu announced this week that highly-respected Venture Capital (VC) Firm, Shanghai Zhangjiang Science &Technology Investment Corporation (ZJSTIC) is the latest partner to invest in what the 2015 Nobel Prize Laureate Summit on Biomedical Science (NPLS) organizers published earlier this year as, "game changing" and "breakthrough", Anpac early cancer detection technology.
Impressed by promising results generated from over 22,000 case studies, the technology and biomedical focused VC group has invested the equivalency of several million U.S. dollars in Anpac, due to the company's pioneering "Cancer Differentiation Analysis" (CDA) technology.
Anpac's proprietary CDA medical devices effectively reinvent cancer screening and early cancer detection by analyzing simple, standard, non-invasive "Blood Biopsies" – resulting in measurably greater cancer detection sensitivity and specificity, with no harmful side effects in patients. From over 22,000 cases gathered to date, scientists report Anpac's CDA research validity achieves an average sensitivity and specificity rate range of 70%-85% for ten different types of cancer – often identifying the type and location of threatening cancer cells before they form into tumors.
Although a young company, Anpac's encouraging CDA findings have led to ongoing collaborations with almost 140 cooperative medical institutions countrywide; establishing partnerships and forming operations networks that include sample collection, storage, logistics, and sales, in 27 Chinese provinces and four major municipalities.
ZJSTIC leaders project that Anpac's CDA will be the primary cancer screening method serving a significant portion of China's population within five years – and thus an excellent investment opportunity. Partly as a result of ZJSTIC's significant "Series A" investment, Anpac is now establishing a U.S. Headquarters; with a targeted goal of forming American partnerships and seeking approval for CDA U.S. clinical trials next year.
"Anpac is very pleased to announce this new partnership and Series A investment," states Yu. "ZJSTIC has an excellent track record in investing in highly innovative biomedical companies. Many of them have gone on to achieve great success."
Dr. Yu will soon be sharing specific results of Anpac's latest CDA Breast Cancer studies to attendees and other interested parties and media, at the national, "Breast Cancer Symposium" in San Francisco, CA, September 25-27, 2015.
SOURCE Anpac Bio-Medical Science Company, Ltd.